Dopamine rushes, withdrawals, and detoxes are trending among wellness gurus online. But experts say the science behind the ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

Dopamine agonists are the first-line treatment for RLS; their efficacy has mainly been demonstrated by short-term trials of oral medications. Oertel and colleagues (2011) aimed to determine the ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

indicating that the autocrine loop of action of this hormone may be a new therapeutic target Dopamine agonists, the classical drugs used to decrease prolactin production and release from the ...

Methods: A retrospective drug utilization evaluation was conducted in patients who received levodopa or dopamine agonist for RLS from July 1, 2006, to July 31, 2007. Patients' medical records were ...

Semaglutide, known as Ozempic, may reduce alcohol cravings and consumption, offering new addiction treatment possibilities.

Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

“In the brain, GLP-1 receptors act like a stop light and tell certain areas of the brain to stop releasing dopamine ... who took a GLP-1 receptor agonist medication were less likely to be ...